FDA: Mifepristone review won't be done until March

The FDA has delayed the release of its long-awaited safety review of mifepristone until March, while also confirming it will not introduce any new restrictions on the abortion pill before then. The announcement comes amid growing frustration from anti-abortion groups, who have criticized the agency’s handling of the drug’s regulatory process. Legal and political tensions surrounding mifepristone remain unresolved as the review period extends. The decision may deepen divisions over access to the medication in the coming months.

The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point. The revelations are likely to further anger anti-abortion activists, who have been losing patience with the...